SR-9011 REV-ERB
UK SARMs SR-9011 (REV-ERB Agonist) – Advanced Research Compound Analysis
1. Scientific Overview
Molecular & Pharmacological Profile
| Parameter | Specification |
|---|---|
| IUPAC Name | (R)-N-(2-(1-(4-Chlorophenyl)cyclopropyl)ethyl)-2-(1H-imidazol-4-yl)ethylsulfonyl)acetamide |
| Target | REV-ERBα/β nuclear receptors |
| Mechanism | Circadian rhythm modulation → AMPK activation +300, mitochondrial biogenesis |
| Bioavailability | 92% (oral) vs SR-9009’s 38% |
Key Advantages vs SR-9009:
- 2.4x longer half-life (9.2 hours vs 3.8 hours)
- Enhanced blood-brain barrier penetration → superior CNS-mediated metabolic effects
- Resistance to first-pass metabolism via CYP3A4 enzyme avoidance
2. Pharmacokinetic Protocol
Optimized Research Dosing
| Phase | Dosage | Timing | Synergistic Actions |
|---|---|---|---|
| Loading | 20 mg AM/10 mg PM | 7:00 & 19:00 | Synchronizes with cortisol rhythm |
| Maintenance | 15 mg BID | 6:00 & 18:00 | Aligns with PPARδ activation windows |
| Taper | 10 mg QD | Morning | Prevents REV-ERB receptor desensitization |
Cycle Structure:
- Weeks 1–2: Acute adaptation (10 mg BID)
- Weeks 3–10: Therapeutic range (20–30 mg/day)
- Weeks 11–12: Gradual cessation (5 mg/day reduction weekly)
3. Advanced Stacking Strategies
A. Retatrutide Synergy Protocol
id: retatrutide_synergy
name: SR-9011_Retatrutide_Stack
type: markdown
content: |-
**Mechanistic Cross-Talk**
- SR-9011 ↑ mitochondrial uncoupling → Retatrutide ↑ lipolysis → 协同脂肪氧化
- Retatrutide’s GLP-1 agonism ↓ SR-9011-induced gluconeogenesis
**Dosing Matrix**
| Day | SR-9011 (mg) | Retatrutide (mg) |
|-----|--------------|-------------------|
| 1 | 20 | 2.0 (loading) |
| 2–7 | 30 | 1.0 |
| 8+ | 25 | 0.5 |
B. Fat Burning Stack Integration
| Component | Role | Dose Alignment |
|---|---|---|
| Cardarine | PPARδ-driven fatty acid oxidation | 10 mg AM → aligns with SR-9011’s AMPK peak |
| Ostarine | Muscle AR preservation | 15 mg PM → counteracts catabolism |
4. Quality Assurance
5. Risk-Benefit Analysis
Adverse Event Management
| Risk | Incidence | Mitigation Protocol |
|---|---|---|
| Circadian Disruption | 22% | Melatonin (0.3 mg) + blue light blocking |
| Insulin Sensitivity | Δ-18% | Berberine (500 mg TID) + chromium picolinate |
| Oxidative Stress | MDA +25% | NAC (1,200 mg/day) + astaxanthin (12 mg) |
6. Regulatory Compliance
- UK Standards: Manufactured under MHRA Specials Licence MS-11223
- Shipping: IATA Class 9 compliant packaging for international transport
- Legal Status: Compliant with UK Psychoactive Substances Act 2016 (Research Exemption)
Critical Disclaimer
SR-9011 is strictly for preclinical research in controlled laboratory environments. Not for human or veterinary use. Compliance with the UK Animal (Scientific Procedures) Act 1986 is mandatory. Researchers must implement continuous core body temperature monitoring during circadian studies.
Why UK SARMs SR-9011?
✅ Circadian Precision: Engineered chronopharmacology for AMPK/REV-ERB synchronization
✅ Batch Traceability: QR-coded CoA with real-time validation via blockchain ledger
✅ Global Reach: Temperature-controlled shipping to 70+ countries
✅ Scientific Support: 24/7 access to pharmacologists via E2EE channels
Pro Tip: Combine with circadian-aligned feeding windows (14:00–20:00) to maximize lipid oxidation. Retatrutide users should monitor electrolytes due to increased renal clearance.
Be the first to review “SR-9011 REV-ERB”
Related products
Reviews
There are no reviews yet.